ARTICLE | Company News
Selecta, Bill & Melinda Gates Foundation, NIH drug delivery, neurology, infectious news
June 30, 2014 7:00 AM UTC
Selecta received a $8.1 million grant from NIH’s National Institute on Drug Abuse (NIDA) to develop SEL-068, a nicotine vaccine for smoking cessation and relapse prevention. The targeted synthetic vaccine particle (tSVP) that activates immune responses has completed a Phase I trial. In 2010, NIDA provided $3 million in funding for the program. ...